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Abstract
Asymptomatic Alzheimer disease (ASYMAD) is characterized by normal cogni-
tion despite substantial AD pathology. To identify factors contributing to cognitive
resilience, we compared early changes in regional cerebral blood ﬂow (rCBF) in
individuals subsequently diagnosed as ASYMAD with changes in cognitively im-
paired (CI) and normal older participants from the Baltimore Longitudinal Study
of Aging. Participants underwent annual positron emission tomography (PET)
rCBF measurements beginning 10.0 (SD 3.6) years before death and while cogni-
tively intact. Based on clinical and autopsy information, subjects were grouped as
cognitively normal (CN = 7), ASYMAD (n = 6), and CI (=6). Autopsy material
was analyzed using CERAD and Braak scores and quantitative stereologic mea-
sures of tau and amyloid. ASYMAD and CI groups had similar CERAD and Braak
scores, similar amounts of β-amyloid and tau in middle frontal (MFG), middle
temporal (MTG), and inferior parietal (IP) regions, and more β-amyloid than CN
in precuneus, MFG, and IP areas. Voxel-based PET analysis identiﬁed similarities
and differences in longitudinal rCBF change among groups across a 7.2-year inter-
val. Both ASYMAD and CI groups showed similar longitudinal rCBF declines in
precuneus, lingual, and MTG regions relative to CN. The CI also showed greater
rCBF decreases in anterior and posterior cingulate, cuneus, and brainstem regions
relative to ASYMAD and CN, whereas ASYMAD showed greater relative rCBF in-
creases over time in medial temporal and thalamic regions relative to CI and CN.
Our ﬁndings provide evidence of early functional alterations that may contribute
tocognitiveresilienceinthosewhoaccumulateADpathologybutmaintainnormal
cognition.
Introduction
Alzheimerdisease(AD)isaneurodegenerativedisorderclin-
ically characterized by progressive dementia. The cardinal
pathologic features include accumulations of both extracel-
lular Aβ peptide in neuritic plaques (NPs) and intracellular
hyperphosphorylated tau in neuroﬁbrillary tangles (NFTs).
These two lesions form the basis of current diagnostic crite-
riaofAD(CERAD ,Braak),y etbothha v ebeendemonstrat ed
in cognitively normal (CN) elderly adults (Tomlinson et al.
1968;Crystaletal.1988;Katzmanetal.1988;BraakandBraak
1991;Mirraetal.1991;Mochizukietal.1996;Troncosoetal.
1996; Price and Morris 1999; Knopman et al. 2003).
Thisstate,whichwehavetermedasymptomaticAD(ASY-
MAD) (Riudavets et al. 2007; Iacono et al. 2008), and others
have called preclinical AD (Schmitt et al. 2000), or high-
pathology controls (Benzing et al. 1993), suggests that some
individuals are resistant to the effects of AD pathology. Re-
cent investigations of individuals with ASYMAD have begun
torevealpossibleunderlyingmechanismsresponsibleforthis
c   2012 The Authors. Published by Wiley Periodicals, Inc. This is an open access article under the terms of the Creative
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Table 1. Subject characteristics (mean [SD]).
Group All subjects CN ASYMAD CI
n 19 7 6 6
Sex (M/F) 15/4 7/0 4/2 4/2
Age @ baseline PET 76.0 (7.1) 78.4 (7.6) 75.9 (8.0) 73.2 (5.4)
Age @ death 85.9 (5.3) 87.3 (5.0) 85.5 (6.7) 84.8 (4.8)
First to last PET (years) 7.2 (2.1) 6.3 (3.0) 7.3 (1.3) 8.1 (0.8)
Last PET to death (years) 2.8 (2.1) 2.7 (2.2) 2.3 (2.1) 3.2 (2.3)
APOE 4 positive 4 0 2 2
Hypertension 9 2 3 4
Smokers 2 1 0 1
Diabetes 5 1 2 2
Education 16.4 (3.2) 16.1 (4.1) 17.2 (2.9) 16.0 (2.8)
Mean (SD) values are shown. There were no signiﬁcant differences among groups regarding age at baseline, age at death, time interval between ﬁrst
and last PET, time interval between last PET scan and death, or other health-related measures examined.
resilience.Forexample,ASYMADsubjectshaveneuronalhy-
pertrophyintheCA1regionofthehippocampusandanterior
cingulate cortex (Riudavets et al. 2007; Iacono et al. 2009a).
Neuronal nuclear and nucleolar hypertrophy has also been
demonstrated in the hippocampus, anterior and posterior
cingulate cortices, and primary visual cortex of these indi-
viduals (Iacono et al. 2008).
The current study investigates differences in longitudinal
changes in brain activity among groups of individuals who
eventually follow divergent clinical and pathological trajec-
tories. This study is unique in that cerebral blood ﬂow (CBF)
positron emission tomography (15O-PET) scans were ob-
tained on average 10.0 (SD 3.6) years prior to death when all
participantswereCN.Thus,weareabletoassessantemortem
brain changes in individuals who have AD pathology years
lateratautopsyyetmaintainednormalcognition(ASYMAD)
and compare them to those with AD pathology and cogni-
tive impairment (CI) as well as those who remained CN and
histologically normal.
By examining changes in brain activity demonstrated by
the PET imaging, we can assess both similarities and differ-
ences in premorbid brain function across the groups. Here,
weassesssimilarchangesovertimeinbothASYMADandCI
groupsthatmayreﬂecttheeffectsofsimilarlevelsofdevelop-
ingneuropathology.Wealsoidentifydifferencesdistinctiveto
theASYMADgroupthatmayhelpmaintaincognitiveability
in the face of accumulating neuropathology, and we describe
changes distinctive to CI group that likely contribute to CI
over time in this group.
Materials and Methods
Subjects
In this study we used PET data from 19 older participants
in the neuroimaging substudy (Resnick et al. 2000) of the
BLSA who underwent postmortem evaluation of the brain
(four female, 15 male). Approximately half the BLSA neu-
roimaging substudy participants have agreed to autopsy, a
rate that is similar to that in the BLSA as a whole. These
groups have similar ages, male/female distribution, years of
education,andnumberofAPOEe4alleles(datanotshown).
The mean (SD) age at PET baseline was 76.0 (SD 7.1) years
and age at death was 85.9 (SD 5.3) years. Subjects had to
have at least two PET scans, although the majority had more
than seven scans (n = 1 5 ) .A ta u t o p s y ,s u b j e c t sw e r ed e t e r -
mined to meet pathologic criteria for one of the three study
groupsandindividualswerenotincludediftheyhadevidence
of a non-Alzheimer neurodegerative disorder (e.g., non-AD
tauopathy, Parkinson disease, or vascular dementia). All in-
dividuals remained in good physical and cognitive health
during the period of PET data collection with no history of
central nervous system disorders, major psychiatric disor-
ders including depression, or severe cardiovascular disease
(Table 1).
This study was approved by the local Institutional Review
Boards. All participants provided written informed consent
prior to each assessment.
Study design
ThisstudyexaminesserialCBFmeasurementsstartingmany
years prior to death. Participants underwent PET scanning
sessions at baseline and annually for up to eight follow-up
visits (mean interval 7.2 years). Participants died on aver-
age 2.8 years after the last PET scan included in this study
and underwent autopsy at that time. The study groups were
determined based on the combination of antemortem clini-
cal diagnosis and autopsy ﬁndings (see below). The imaging
analysesweresubsequentlyperformedcomparingthesethree
groups.
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Cognitive assessment
All participants were followed annually and were reviewed
at a consensus conference if their Blessed Information Mem-
ory Concentration score was ≥4, or if their informant or
subjectClinicalDementiaRating(CDR)scorewas≥0.5.De-
mentia diagnosis was determined according to Diagnostic
and Statistical Manual of Mental Disorders, 3rd Ed., Revised
(DSM-III-R) criteria. Mild CI (MCI) diagnosis was based on
the Petersen (Petersen 2004) criteria.
Abatteryofneuropsychologicaltestswasadministeredan-
nually and performance levels were used to determine clini-
cal diagnosis (see Kawas et al. 2000 for detailed description).
These tests included the CDR scale, Blessed Mental Status
(BMS)test,Mini-MentalStateExamination,BuschkeImme-
diate and Delayed Cued Recall, Boston Naming Test, Con-
trolled Verbal Fluency, Trail Making Tests A and B, Clock
Drawing, and the Center for Epidemiologic Studies Depres-
sion Scale.
The annual rate of change in cognitive performance on
each test was calculated using linear mixed models. Overall
differences in baseline (year 1) and annual rates of change
werecomparedacrossallgroups,followedby pairwisegroup
comparisons.
Neuropathologic assessment
At autopsy, the right hemibrain was coronally sliced and
frozen, and the whole left hemibrain was ﬁxed in 10%
buffered formaldehyde for at least 2 weeks and subsequently
sectioned in the coronal plane. Routine diagnostic sections
were obtained from the middle frontal gyrus (MFG), the su-
perior and middle temporal gyri (SMTG), the inferior pari-
etal(IP)lobule,theprimaryvisualcortex,theanteriorcingu-
late, the amygdala, the hippocampus and entorhinal cortex,
basalgangliaandbasalforebrain,thethalamus,midbrainin-
cluding the substantia nigra, pons, medulla, spinal cord, and
cerebellum. Tissues were processed, embedded in parafﬁn,
cut at 10 μm, and stained with hematoxilyn and eosin and
with silver Hirano method (Yamamoto and Hirano 1986).
Lewy body (LB) pathology was assessed in the brain stem
andanteriorcingulatecortexwithalpha-synucleinimmuno-
histochemistry(Synuclein1TransductionLaboratories,Palo
Alto, CA, USA; dilution, 1:500).
Silverstainedsectionswereusedinthestandardassessment
ofADpathologyaccordingtoCERADguidelines(Mirraetal.
1993).NPdensitywasdeterminedintheMFG,SMTG,andIP
lobule and a CERAD age-related plaque score was assigned:
0 = none, A = sparse, B = moderate, C = frequent (Mirra
etal.1993).Incombinationwiththeclinicaldata,apathologi-
caldiagnosisofnormalwithrespecttoAD,possibleAD,prob-
able AD, or deﬁnite AD was rendered according to CERAD
guidelines.Asanadditionalapproachtoassessingtheseverity
of neurodegeneration, the distribution of NFTs was assessed
and graded on a scale of 0–VI according to Braak (Braak and
Braak 1991).
As an adjunct to the standard means of assessing and
diagnosing AD, stereologic analysis was performed using
10 μm sections of the MFG, middle temporal gyrus (MTG),
IP, and precuneus (PreCu) were stained with an antibody
for Aβ-amyloid (6E10, Covance, Emeryville, CA, USA, dilu-
tion 1:500) and phosphorylated tau (PHF-1 antibody; gift of
Dr. P. Davies, dilution, 1:100). Stereological measurements
wereperformedusingaZeisslightmicroscopeequippedwith
a 100´, NA 1.30, oil Plan neoﬂuor ∞/0.10 objective, and in-
terfaced with a Stereo-Investigator system (MBF bioscience,
Williston,VT,USA).Thefractionalareaofimmunoreactivity
was measured utilizing the area fraction fractionator probe.
The gray matter was outlined and an array of 100 points
(150 μm × 150 μm) was placed in a systematic random po-
sition spaced at 800 μm (MFG 6E10, MFG PHF-1, PreCu
6E10, PreCu PHF-1, IP PHF-1), 900 μm (MTG 6E10), or
1000 μm (MTG PHF-1) intervals. The area fraction was cal-
culatedasthenumberofpointsfallingoveramyloid(plaques)
or tau (NFTs, NP, or neurites) immunoreactivity divided by
the total number of points. Data from the three groups were
comparedusingthenonparametricexactKruskal–Wallistest.
Pairwise comparisons used the exact Wilcoxon two-sample
test to determine the relationship between each group.
PET scanning conditions
Participants underwent PET scanning sessions at baseline
(year 1) and annually for up to eight follow-up visits (mean
interval 7.2 years). During each imaging session, a resting
statePETscanwasperformed.Duringrest,participantswere
instructedtokeeptheireyesopenandfocusedonacomputer
screen covered by a black cloth. For the analyses, scans were
censored at the time of clinical diagnosis of dementia onset,
documentedtransientischemicattack/cerebralinfarction,or
development of seizures.
PET scanning parameters
PET measures of regional CBF (rCBF) were obtained using
[15O] water. For each scan, 75 mCi of [15O] water were in-
jected as a bolus. Scans were performed on a GE 4096+ scan-
n e r ,w h i c hp r o v i d e s1 5s l i c e so f6 . 5 - m mt h i c k n e s s .I m a g e s
were acquired for 60 sec from the time the total radioactivity
counts in brain reached threshold level. Attenuation correc-
tionwasperformedusing atransmissionscanacquiredprior
to the emission scans.
PET data analysis
For each subject, the PET scans were realigned, resliced to a
voxelsizeof2×2×2mm,spatiallynormalizedintostandard
stereotactic, and smoothed to a full width at half maximum
of 12, 12, and 12 mm in the x, y,a n dz planes. To control for
variabilityinglobalﬂow,rCBFvaluesateachvoxelwereratio
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Table 2. Cognitively impaired subjects.
Clinical CERAD No. of PET Year of Year of Year of
Subject diagnosis diagnosis scans included last PET diagnosis death APOE
1 Probable AD Probable AD 8 2001 2002 2002 3/3
2 Probable AD Probable AD 9 2002 2007 2008 3/4
3 Possible AD Probable AD 8 2001 2004 2004 3/4
4 Possible AD + vascular dementia Probable AD 8 2001 2002 2004 3/3
5 Dementia
1 Probable AD 8 2001 2004 2007 3/3
6 Amnestic MCI Possible AD
2 9 2003 2007 2008 2/3
The last PET included in analysis was prior to the diagnosis of dementia.
1This individual exhibited a pattern of cognitive decline consistent with AD, but had one episode of hallucinatory events.
2By CERAD criteria, a subject with an age-related plaque score of B must have clinically diagnosed dementia to be considered probable AD. A clinical
diagnosis of MCI, although included in our cognitively impaired subject group, is only considered possible AD using CERAD criteria.
adjustedandscaledtoameanglobalﬂowof50mL/100g/min
for each image. The image data were analyzed using Statis-
tical Parametric Mapping (SPM5; Wellcome Department of
Cognitive Neurology, London, England), where whole brain
voxel by voxel comparisons determined signiﬁcant similari-
ties and differences in longitudinalrCBF changebetween the
groups. Group × time linear comparisons were performed
to assess (1) similar changes over time in both ASYMAD and
CI groups relative to CN, (2) changes in the ASYMAD group
relative to CI and CN, and (3) changes in the CI group rela-
tive to ASYMAD and CN groups. All contrasts were adjusted
for sex and baseline age at year 1. Signiﬁcant effects for each
contrastwerebasedonthemagnitude(P ≤0.005)andspatial
extent (>50 voxels) of activity. To examine the direction and
patterns of change in signiﬁcant regions, rCBF values were
extracted from 6 mm spherical regions centered on the local
maxima of each region. The rCBF values were then used to
calculate differences in baseline (year 1) levels between the
groups, and to calculate and compare mean trajectories of
changeovertimeforeachgroupusinglinearmixedmodels.
Results
Clinical diagnosis
Allparticipantsremainedcognitivelyintactduringtheperiod
inwhichPETscanswereperformed.Thirteenparticipantsre-
mainedCNbyconsensuscriteria(Kawasetal.2000)through
the last available cognitive evaluation (last evaluation on av-
erage was 14.8 months prior to death, range 3–30 months).
The remaining six individuals developed some degree of CI
(last evaluation on average 2.8 months prior to death, range
1–5months)byconsensuscriteria.Onedeclinedtoamnestic
MCI (Petersen 2004), one to possible AD (n = 1), two to
probableAD,onetodementiaofundeterminedetiologythat
was consistent with probable AD on pathology (n = 1), and
o n et om i x e dv a s c u l a rd e m e n t i aa n dA D( n = 1) (Table 2).
Autopsy diagnostic evaluation
All brains from subjects with CI had NP CERAD age-related
plaque scores of B and NFT Braak scores of III (n = 2),
IV (n = 3), and V (n = 1). Among the 13 subjects that
remained CN, six had substantial AD pathology, that is, NP
age-related scores of B and NFT Braak scores of II (n = 1),
III (n = 2), or IV (n = 3). The remaining seven CN subjects
had NP CERAD age-adjusted plaque scores of 0 (n = 6) or A
(n=1),andNFTBraakscoresofII(n=3),III(n=1),orIV
(n = 3) (Table 3; Braak and Braak 1991; Mirra et al. 1991).
Ten (4/6 CI, 1/6 ASYMAD, 5/7 CN) participants had evi-
dence of remote microinfarcts or lacunes at the time of au-
topsy. The majority of these were located in the basal ganglia
Table 3. CERAD and Braak scores.
CERAD age-adjusted plaque score Braak neuroﬁbrillary tangle score
Group 0 A B C I II III IV V VI
C N 61000313 00
A S Y M A D00600123 00
C I 00600013 20
Number of individuals per group with each plaque or NFT score. The CERAD scores represent: 0 = no neuritic plaques A = sparse neuritic plaques,
B = moderate neuritic plaques, C = frequent neuritic plaques. Braak score is determined as per Braak and Braak (1991). Low Braak stages (1–II) have
NFTs in the entorhinal cortex (I) and hippocampus (II), mid Braak stages (III–IV) have NFTs extending to the neocortical association areas, and high Braak
stages (IV–V) have NFTs extending to the parastriate (V) and striate (VI) cortices.
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or cerebellum. One subject in the CI group had an acute in-
farct in the distribution of the right middle cerebral artery.
An u m b e ro fo t h e rp a t h o l o g i e sw e r ef o u n di ns u b j e c t si nt h e
CN,eachoccurringinonesubject.Theseincluded:LBpathol-
ogy limited to rare LB in the substantia nigra, the amygdala,
and temporal cortex corresponding to a brainstem distribu-
tion of α-synuclein pathology (McKeith et al. 2005); inac-
tive demyelinating lesions consistent with multiple sclerosis,
whichwereincidentallydiscovered;focalperivascularcufﬁng
with mononuclear cells in a few vessels in the basal ganglia;
and focal areas of tau positive astrocytes in the amygdala and
substantia nigra. In all cases, NP and NFT evaluations and
quantitativestereologywereperformedintissuesectionsnot
affected by these non-AD-related ﬁndings.
Deﬁnition of groups according to
clinical/cognitive-pathological correlations
Based on the clinical and neuropathologic diagnoses, we
divided the 19 participants into three groups: CN (n = 7,
7males,0females),asymptomaticAlzheimer’sdisease(ASY-
MAD; n = 6, 4 males, 2 females), or cognitively impaired
(CI; n = 6 ,4m a l e s ,2f e m a l e s ) .C Nw e r eC Ni n d i v i d u a l sb y
clinical consensus criteria (Kawas et al. 2000) and also had
none to sparse numbers of NP (CERAD age-related plaque
score 0 or A), Braak scores ranging from II to IV, and re-
ceivedaneuropathologicdiagnosisofnormalwithrespectto
AD by CERAD criteria (Mirra et al. 1991). ASYMAD were
CN by consensus criteria and had moderate numbers of NP
(CERAD age-related plaque score B), Braak scores ranging
from II to IV, and received a neuropathologic diagnosis of
possible AD by CERAD criteria. CI showed variable degrees
ofCI,whichincludedtheclinicaldiagnosesofamnesticMCI
(n = 1) (Petersen 2004), possible AD (n = 1), probable AD
(n = 2), demented (n = 1), and mixed vascular dementia
and AD (n = 1) at the time of death. All individuals in the
CI group had moderate NP (CERAD score B), Braak scores
ranging from II to V, and received a neuropathologic diag-
nosis of possible (N = 1, subject with MCI) or probable AD
(n = 6) by CERAD criteria.
There were no signiﬁcant differences in the number of
years of education (CI 16.0 SD 2.4, ASYMAD 17.7 SD 2.9,
and CN 16.1 SD 4.1) or baseline Primary Mental Ability Test
(PMA) Vocabulary Test score (CI 33.7 SD 11.0, ASYMAD
39.9 SD 2.9, and CN 38.6 SD 7.0) among the three groups.
On the tests used to determine clinical diagnosis, there were
no baseline (year 1) differences between the groups. When
examining the annual rates of change in performance, the
BMS (P = 0.006), Boston Naming (P = 0.03), and Trails B
(P = 0.006) tests showed overall group differences. Follow-
up comparisons revealed that the CI group showed greater
decline than the CN group on the Boston Naming task
(P = 0.01), and greater decline than both CN and ASYMAD
groupsontheTrailsBtest(P’s <0.03).TheASYMADgroup,
althoughstillconsideredCN,showedgreaterdeclinethanthe
CI group on the BMS exam (P = 0.002). The last available
CDRscalescoreswereobtainedonaverage11months(range
1–30months)priortodeathandweresigniﬁcantlygreaterin
the CI group than the ASYMAD (P < 0.005) and CN groups
(P < 0.05).
There were no signiﬁcant differences between the groups
inthenumberofindividualswhowerepositivefortheAPOE
e4allele,asbothCIandASYMADgroupshadtwoindividuals
withanAPOEgenotypeof3/4.Therewerealsonodifferences
in the number of individuals with history of hypertension,
smoking, or diabetes during the study.
Table 3 shows the semiquantitative neuropathologic as-
sessment of CERAD and Braak scores. The CI and ASY-
MAD groups had identical CERAD NP scores (all subjects
CERAD age-related plaque score B). The CN group had less
NP pathology than both the ASYMAD and CN groups. The
majorityofCNsubjects(n=6)hadnoNP ,whileonesubject
had sparse NP (CERAD age related plaque score A). There
was no difference in Braak scores among the three groups.
Stereology
TwosubjectsintheCNgroupdidnothaveadequatematerial
to perform quantitative stereology on the MTG. For all other
areas (MFG, IP, precuneus) material was available from all
19 subjects.
The CI and ASYMAD groups showed no signiﬁcant dif-
ference in amyloid (both neuritic and diffuse plaques) in the
MFG and IP. CI had greater β-amyloid in the PreCu and
MTG (P < 0.05) than both CN and ASYMAD. ASYMAD
andCIhadmor eβ-amyloidthanCNinMFG,PreCu,andIP
(P ≤ 0.05). Additionally, CI had greater β-amyloid than CN
in theMTG (P ≤ 0.05). Table4 shows the meanarea fraction
of β-amyloid immunoreactivity in the MFG, MTG, IP, and
PreCu in the three groups.
There was no signiﬁcant difference between CI and ASY-
MADorbetweenASYMADandCNinthemeanareafraction
of tau in any of the four regions. CI had signiﬁcantly greater
tau than CN in all four regions (P < 0.05). ASYMAD and
CNdidnotshowsigniﬁcantdifferencesintheamountoftau,
yet the ASYMAD group showed a trend toward greater tau
in the MFG as compared with CN (P = 0.07). Table 4 shows
the mean area fraction of tau immunoreactivity in the MFG,
MTG, IP, and PreCu in the three groups.
PET imaging
Intermsoflongitudinalchange,someregionsshowedsimilar
declines in rCBF over time in both ASYMAD and CI groups
relative to CN. These declines were observed in bilateral pre-
cuneus(BrodmannArea7)[stereotacticcoordinate:−6−48
42], lingual gyrus (BA 18) [0 −60 4], and superior aspects of
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Table 4. Fractional areas of β-amyloid and tau.
Mean (SD) fractional area tau Mean (SD) fractional area amyloid
Group MFG MTG PreCu IP MFG MTG PreCu IP
CN 0 0.0017 0 0.0043 0.73 0.52 0.40 0.45
(0) (0.0041) (0) (0.011) (1.9) (1.3) (1.1) (1.2)
ASYMAD 0.74 0.050 0.0067 0.033 2.6 1.5 0.91 1.1
(1.8) (0.087) (0.016) (0.072) (1.3) (0.18) (0.75) (1.3)
CI 0.23 0.33 0.018 0.29 4.0 3.1 2.4 2.3
(0.33) (0.29) (0.026) (0.33) (1.3) (1.3) (1.4) (1.0)
All values have been divided by a factor of 10
2. There are no signiﬁcant differences (P ≥ 0.05) in the mean area fractions of amyloid between ASYMAD
and CI in the MFG, MTG, and IP.
There are no signiﬁcant differences (P ≥ 0.05) in the mean area fractions of tau between ASYMAD and CI in any of the l four regions.
CI has signiﬁcantly more tau and amyloid (P ≤ 0.05) than CN in all four regions.
Figure 1. Common areas of rCBF decline in ASYMAD and CI groups. Regions that show similar rCBF decline over time in ASYMAD and CI groups.
Precuneus, lingual gyrus, and bilateral middle temporal regions bordering on inferior parietal cortex are shown. Trajectories of CBF change over time
are shown for precuneus and middle temporal regions. All regions show a rate of decline that is signiﬁcantly greater than CN (P’s ≤ 0.001).
the MTG bordering on IP cortex (BA 39) [54 −64 16; −50
−68 −22] (Fig. 1).
The analyses also showed signiﬁcant differences in rCBF
change among the ASYMAD, CI, and CN groups (Fig. 2).
These differences are described in terms of the direction and
pattern of rCBF change among groups. In ASYMAD, several
regionsshowedincreasesinCBFovertimerelativetoboththe
CI and CN groups. These regions included the right anterior
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Figure 2. rCBF changes distinctive to ASYMAD and CI groups. Areas where ASYMAD and CI show longitudinal changes in rCBF. Regions in red
illustrate areas that increase rCBF over time in ASYMAD relative to CI and CN groups. Regions in blue illustrate regions that decrease rCBF over time
in CI relative to ASYMAD and CN groups. Cerebellar and cuneus regions in green are areas that show increased rCBF over time in CN but not CI.
Trajectories of CBF change are shown for hippocampal and anterior insular regions, where ASYMADs show increased CBF over time; trajectories of
change in posterior insula and middle temporal regions show decreased CBF in the CI group.
insula [40 12 4], right hippocampus and parahippocampal
gyrus(BrodmannArea30)[26−368],andbilateralthalamic
regions[20−182;−30−222].LongitudinalrCBFintheleft
parahippocampal gyrus (BA 30) [−8 −36 4] was also higher
intheASYMADgroupovertime,butthiswasduetostability
of CBF in this group in conjunction with a decline over time
in the CN group.
TheCIgroupshowedgreaterrCBFdeclinesthanASYMAD
and CN in several regions. These included the right anterior
cingulate(BA32)[61828],rightposteriorcingulate(BA23)
[10 −42 24], right posterior insula [60 −6 16], left cuneus
(BA 18) [−2 −80 34], and bilateral brainstem [−2 −18 −8;
14 −26 −14] areas. There was also an area in the right MTG
(BA 21) [56 −48 10] that showed both a decrease in CI and
an increase in ASYMAD and CN. The CI group also showed
e f f e c t i v ed e c l i n e so v e rt i m ei nt h er i g h tc u n e u s( B A1 8 )
[6 −72 16] and left cerebellum [−2 −56 −6] that were re-
ﬂected as a failure to increase rCBF over time as observed in
the CN group. Because these are relative changes in CBF, the
apparent CBF increases in ASYMAD and CN groups could
actually reﬂect stability of CBF change over time in these
latter two instances. The differences between CI and other
groups, however, still result from greater decline in CBF in
the CI group.
Within the regions of longitudinal change, there were no
signiﬁcant differences in baseline (year 1) CBF with one ex-
ception.Theanteriorcingulateregion(BA32),whichshowed
greaterlongitudinaldeclineintheCIgrouprelativetotheCN
and ASYMAD groups, had baseline CBF levels that were sig-
niﬁcantly different across groups (P = 0.04). This effect was
driven by higher initial baseline levels in the CI group than
t h eA S Y M A Dg r o u p( P = 0.01).
Discussion
In this study, we compared longitudinal changes in rCBF in
BLSA participants classiﬁed as CN, ASYMAD, and CI based
on clinical data and neuropathological ﬁndings at autopsy.
Acrossthegroups,weobservedsigniﬁcantdifferencesinbrain
activity over time measured many years before death and
whileall participantswereCN. TheASYMAD andCIgroups
differed from CN in several areas, suggesting that some re-
gions show similar functional loss due to neuropathologic
changes in the brain. Changes distinctive to either ASYMAD
or CI groups were also noted. Because these differential pat-
terns of CBF were identiﬁed years prior to the development
of CI and death, these functional changes may be related to
the difference in subsequent cognitive ability between these
groups.
The CI and ASYMAD groups exhibited similar amounts
of neuropathology at autopsy. The CI and ASYMAD groups
not only had identical scores for NPs, which is based on
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the current criteria used in the neuropathologic diagnosis
of AD, but they also had similar cortical burdens of pathol-
ogy by quantitative assessments of β-amyloid. Additionally,
Braak scores were not signiﬁcantly different between these
groups, indicating a comparable distribution of NFTs, which
was strengthened by the demonstration of similar quantita-
tive assessments of cortical tau (NFTs and threads) in the
ASYMAD and CI groups.
Based on these results, it could be hypothesized that the
CI and ASYMAD groups would show similar differences in
brain function when compared to pathologically normal in-
dividuals. Indeed, both of the groups with AD pathology
showed similar longitudinal declines in rCBF in the pre-
cuneus, lingual gyrus, and middle temporal regions. As the
precuneus and middle temporal regions demonstrated sim-
ilar mean area fractions of amyloid and tau in both CI and
ASYMAD groups, these results suggest that premorbid func-
tion in these regions may decline with the accumulation of
the neuropathology over time. However, the functional de-
cline in these regions is likely not the primary contributor to
thesubsequentdifferencesincognitiveability,asthedeclines
occur in individuals who maintaincognitive ability as well as
those who develop impairments.
The ASYMAD and CI groups also demonstrated distinc-
tive changes in brain function. The ASYMAD group showed
longitudinal increases in rCBF in the anterior insula, hip-
pocampus and parahippocampal gyrus relative to both CI
and CN groups. These functional differences occurred even
though all three groups had similar Braak scores, indicating
similar amounts of tau in the medial temporal lobe. The fact
that ASYMAD, CI, and CN groups have tau in the medial
temporal lobe argues against increased rCBF in response to
the presence neuropathology alone. Instead, previous evi-
dence of neuronal plasticity from other cases from the BLSA
may support these functional differences. It has been shown
that hippocampal neurons exhibit hypertrophy of the cell
body, nucleus, and nucleolus in ASYMAD that is not ob-
served in individuals with MCI or AD (Riudavets et al. 2007;
Iacono et al. 2008; Iacono et al. 2009a); a ﬁnding that has
been replicated in cases from the Nun Study (Riudavets et al.
2007; Iacono et al. 2008; Iacono et al. 2009a). Furthermore,
in the neurons of ASYMAD there is increased expression of
cyclins (M. Riudavets, unpubl. ms.) and of mRNA for mul-
tiple synaptic proteins (Iacono et al. 2009b). Together, these
cellular and brain activity changes suggest the possibility of
compensatory processes in ASYMAD subjects that may con-
tribute to cognitive resilience in the face of substantial AD
pathology.
The CI group, conversely, showed decreased rCBF in sev-
eral regions relative to ASYMAD and CN. These included
rCBF declines in the anterior and posterior cingulate, the
cuneus, and the brainstem. Previous studies lend support
to these ﬁndings, in that these regions show early metabolic
decreases in AD (Mosconi 2005), and rCBF in the posterior
cingulate cortex correlates with Braak NFT scores (Bradley
et al. 2002). In terms of function, the cingulate regions are
thought to participate in higher order cognitive functions
(Binder et al. 2009; Medford and Critchley 2010) and have
also been implicated in the default mode network of resting
statebrainactivity(Shulmanetal.1997;BucknerandVincent
2007), the disruption of which may impact cognitive ability
in the aging brain (Lustig et al. 2003; Grady et al. 2006). To-
gether, these declines in brain activity may be related to the
decline in cognitive function that ultimately occurred in the
impaired group.
The differential patterns of rCBF between the ASYMAD
and CI groups are intriguing since they occurred in groups
with similar pathologic features but divergent clinical out-
c o m e s .H o w e v e r ,d u et ot h es m a l ls i z eo ft h es t u d yg r o u p ,i t
is possible that we were not able to detect a difference in the
amountoftauoramyloidbetweentheCIandASYMADsub-
jects. Nevertheless, our observations of differences in rCBF
forASYMADcomparedwithCNandCI,inconjunctionwith
differences in neuronalsize and protein and gene expression,
supporttheconceptofaprocessuniquetoASYMADsubjects,
which allows them to resist the potentially deleterious effects
of accumulating pathology. Had the ASYMAD individuals
survived longer, however, it is possible that cognitive decline
eventually would have occurred once the pathologic burden
reachedacriticalthresholdorwhenthecompensatoryevents
werenolongersufﬁcient.Whilesomeinvestigatorsarguethat
variability in cognitive reserve may account for resistance to
pathology in ASYMAD (Stern 2009), our groups did not sig-
niﬁcantly differ with respect to years of education or PMA
Vocabulary, both proxies for cognitive reserve.
Although this study has a limited number of subjects, it is
distinctive in that subject groups were based on both clinical
and pathologic features. As the majority of studies evaluat-
ing brain activity classify individuals clinically, there are only
limited studies evaluating rCBF in subjects with pathologi-
callyconﬁrmeddiagnoses(Jobstetal.1992;Bonteetal.1993;
Jobst et al. 1997; Jagust et al. 2001; Bradley et al. 2002), and
these primarily focused on the utility of rCBF in diagnosis
of AD. Our study also offered the unique opportunity to
evaluate longitudinal differences in rCBF not only in nor-
mal and impaired subjects, but in the group of individuals
withAlzheimerpathologywhoretainnormalcognition,that
is, ASYMAD individuals, and appear to be resistant to the
deleterious effects of AD pathology.
Due to the small sample size of our study, the ﬁndings are
preliminary and a larger cohort is needed to conﬁrm and
extend these results and perhaps uncover additional vari-
ations among the groups. However, compared to the full
BLSA autopsy cohort, our participants are representative of
this larger sample in terms of age, sex ratio, education, and
APOE status. Despite the small number of subjects, we were
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able to identify differential patterns of activity years prior to
death indicating differences in brain function between sub-
j e c t sw h ow i l lu l t i m a t e l yd e v e l o pC Ii na s s o c i a t i o nw i t hA D
pathology and those who remain cognitively intact. These
changes may represent compensatory processes or perhaps
the utilization of alternative brain networks in the face of ac-
cumulating pathology. This study provides further evidence
that ASYMAD subjects are a unique group of individuals
characterized by intact cognitive and brain function despite
AD pathology.
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